related to Type 1 diabetes
Tyrosine Phosphatase Autoantibodies
A plasma lipoprotein
Interferon-gamma
essential in diagnosing and managing allergic diseases
This test measures levels of Insulin-Like Growth Factor 1 (IGF-1) using liquid chromatography–mass spectrometry (LC/MS), one of the most accurate and specific testing methods available. IGF-1 plays a critical role in growth, metabolism, and cellular repair, and its levels reflect growth hormone (GH) activity in the body. Why Is IGF-1 Testing Important? IGF-1 testing is used to: Evaluate growth disorders in children and adults Diagnose and monitor acromegaly (excess growth hormone) Support diagnosis of growth hormone deficiency (GHD) Guide and monitor GH or IGF-1 replacement therapy Clinical Insights High IGF-1 levels may indicate acromegaly, a condition where the body produces too much growth hormone. IGF-1 levels are used both for diagnosis and to monitor treatment after surgery or with medications (e.g., somatostatin analogs, pegvisomant). Low IGF-1 levels may suggest growth hormone deficiency (GHD), especially in individuals with multiple pituitary hormone deficiencies or genetic conditions. IGF-1 is also useful in adjusting GH replacement therapy in both children and adults. Why LC/MS Testing Is Superior Most IGF-1 tests use immunoassays, which can give inaccurate results due to interference from IGF binding proteins (IGFBPs). LC/MS testing offers several advantages: Highly specific: Accurately measures intact IGF-1, minimizing interference from IGFBPs. Sensitive and reliable: Offers excellent precision with a coefficient of variation (CV) ≤5%. Detects rare IGF-1 variants, which may be missed by immunoassays. Standardized to WHO reference materials for consistent, comparable results. Note: LC/MS may yield lower IGF-1 levels than traditional immunoassays. This is due to technical differences, not necessarily a reflection of true biological variance. Always use the same method consistently for monitoring over time. Who Should Be Tested? This test is appropriate for individuals who may have: Short stature or delayed growth in children Gigantism or acromegaly symptoms (enlarged hands/feet, facial changes) Pituitary tumors or prior pituitary surgery Suspected adult growth hormone deficiency (especially with panhypopituitarism) Ongoing GH or IGF-1 therapy needing dosage adjustment How the Test Works Sample Type: Serum Method: High-resolution LC/MS with isotope-labeled internal standards Analytical Range: 10–2,000 ng/mL Reference Ranges: Adjusted by age and sex, based on data from over 2,000 individuals This method dissociates IGF-1 from its binding proteins and recovers nearly 100% of total IGF-1 for accurate measurement. Understanding Your IGF-1 Results Results are interpreted using Z-scores, which compare your IGF-1 level to the average for your age and sex. Z > +2.0: Suggests GH excess (e.g., acromegaly or over-treatment) Z between -2.0 and +2.0: Normal IGF-1 level Z < -2.0: Suggests GH deficiency or under-treatment A normal IGF-1 level does not fully exclude acromegaly or GHD. Follow-up testing (e.g., glucose suppression or GH stimulation) may be required in some cases. Key Considerations Stay consistent: Use the same assay method over time to monitor treatment. Don’t switch platforms without consulting your provider, as values may differ significantly between LC/MS and immunoassays. Rare IGF-1 variants, if present, are reported separately and may affect interpretation but are uncommon (<1% prevalence).
Identify women who are at high risk for developing preëclampsia
helps manage growth and development
Understand what low or high IGF-BP3 levels mean. IGF-BP3 reflects growth hormone activity and IGF-1 function, helping assess metabolism, growth, and overall hormonal health.
IgG Borrelia afzelii The IgG Borrelia afzelii test measures antibodies against Borrelia afzelii, one of the main bacterial species that cause Lyme disease in Europe and Asia. Unlike Borrelia burgdorferi (more common in North America), B. afzelii is especially associated with chronic skin forms of Lyme disease, such as acrodermatitis chronica atrophicans (ACA). What IgG B. afzelii Means IgG antibodies generally appear weeks to months after infection and often persist long-term, even after treatment. A positive IgG B. afzelii result suggests past exposure or ongoing immune memory to the bacteria, which may help clinicians determine whether symptoms are linked to later or chronic stages of Lyme disease. In contrast, IgM antibodies are more indicative of recent infection, so IgG testing provides a complementary view of the immune timeline. Clinical Importance Testing for IgG B. afzelii can be helpful in patients with: Persistent or late-stage Lyme symptoms, particularly skin changes such as ACA Neurological or musculoskeletal issues suspected to be related to European Lyme disease strains A history of tick exposure in endemic regions of Europe or Asia Patient Takeaway A positive IgG B. afzelii result indicates that your immune system has previously recognized this strain of Borrelia. This does not always mean there is an active infection, since IgG can remain detectable for years. Your healthcare provider will interpret the result in the context of your symptoms, exposure history, and other Lyme disease tests.
IgG Borrelia burgdorferi sensu stricto The IgG Borrelia burgdorferi sensu stricto (s.s.) test measures antibodies against the primary species of Borrelia that causes Lyme disease in North America and parts of Europe. This species is strongly linked to arthritis, neurological symptoms, and late-stage Lyme manifestations. What IgG B. burgdorferi s.s. Means IgG antibodies usually appear weeks to months after infection and can remain detectable long after the initial illness. A positive IgG result indicates past exposure or immune memory to B. burgdorferi s.s. and may support the diagnosis of later or persistent Lyme disease. Because IgM antibodies reflect recent infection, IgG testing is often used to assess whether symptoms may be related to a longer-term or chronic stage of infection. Clinical Importance Testing for IgG B. burgdorferi s.s. is most useful in patients who have: Arthritis or joint swelling that develops weeks to months after a tick bite Neurological problems such as meningitis, facial palsy, or peripheral neuropathy Chronic or recurrent Lyme symptoms with a history of tick exposure in endemic areas Patient Takeaway A positive IgG B. burgdorferi s.s. result means your immune system has previously recognized this Lyme-causing bacterium. This does not necessarily confirm an active infection, since IgG antibodies often stay in the blood for years. Your healthcare provider will always interpret the result together with your symptoms, clinical history, and other Lyme disease tests. If your IgG result is reported as equivocal (borderline), antibody levels are near the cutoff and not clearly positive or negative. In this case, repeat or confirmatory testing is usually recommended.
The IgG Borrelia burgdorferi Antigen (Ag) test measures long-term antibodies against antigens of Borrelia burgdorferi, the main bacterium responsible for Lyme disease, particularly in North America. Unlike species-specific tests that focus on one strain, antigen-based assays detect immune responses to a broader range of Borrelia proteins, offering insight into both past exposure and potential later-stage infection. What IgG B. burgdorferi Ag Means IgG antibodies appear weeks to months after infection and may remain present for years, even after treatment. A positive result suggests that your immune system has mounted a previous response to Borrelia antigens, which can be a clue in cases of chronic or late-stage Lyme disease. Because antigens cover multiple Borrelia proteins, this test may capture antibody responses that complement other markers such as OspC, OspA, or VlsE. Clinical Importance Testing for IgG Borrelia burgdorferi Ag can be helpful in patients who have: Persistent Lyme symptoms such as joint pain, neurological issues, or fatigue Evidence of late-stage disease, including Lyme arthritis or neuroborreliosis A history of tick exposure in Lyme-endemic areas where infection risk is high Patient Takeaway A positive IgG B. burgdorferi Ag test means your immune system has recognized antigens from the Lyme disease bacterium. This does not always indicate an active infection, since IgG antibodies may persist long after the original illness. Your healthcare provider will interpret the result together with your symptoms, clinical history, and other Lyme disease markers to build a complete diagnostic picture. If your result is equivocal (borderline), antibody levels are near the cutoff and the finding is uncertain. In these cases, repeat or confirmatory testing is often recommended.
The IgG Borrelia garinii test detects antibodies against Borrelia garinii, one of the main bacterial species in the Borrelia burgdorferi sensu lato complex that causes Lyme disease, particularly in Europe and Asia. This strain is strongly linked with neurological forms of Lyme disease (neuroborreliosis), including meningitis, radiculitis, and cranial nerve involvement. What IgG B. garinii Means IgG antibodies typically appear weeks to months after infection and can remain detectable long after the initial exposure. A positive IgG B. garinii result suggests past exposure or immune memory and may support the diagnosis of later or persistent Lyme disease, especially when neurological symptoms are present. Since IgM antibodies reflect recent infection, IgG testing helps assess whether symptoms may relate to chronic or long-term stages of Lyme disease. Clinical Importance Testing for IgG Borrelia garinii is most useful in patients with: Neurological symptoms such as meningitis-like signs, facial palsy, or nerve pain Chronic or persistent Lyme symptoms following tick exposure in endemic regions Musculoskeletal or systemic issues suspected to be caused by European or Asian Lyme strains Patient Takeaway A positive IgG B. garinii result means your immune system has previously recognized this Lyme-associated bacterium. This does not always indicate an active infection, since IgG antibodies can persist for years after exposure. Your doctor will interpret the result in the context of your symptoms, medical history, and other Lyme disease test findings. If your result is equivocal (borderline), antibody levels are near the cutoff and not clearly positive or negative. In such cases, repeat or confirmatory testing is often recommended.
The IgG Borrelia miyamotoi test detects antibodies against Borrelia miyamotoi, a tick-borne bacterium closely related to Lyme disease pathogens but classified as a relapsing fever Borrelia species. Unlike Borrelia burgdorferi sensu lato (which causes classical Lyme disease), B. miyamotoi is associated with hard-tick relapsing fever (HTRF) and can cause recurring fever episodes, flu-like symptoms, and in some cases, neurological complications. What IgG B. miyamotoi Means IgG antibodies usually develop weeks after infection and may remain detectable for months or years, even after symptoms resolve. A positive IgG result suggests past exposure or immune memory to B. miyamotoi. Because IgM reflects more recent infection, IgG testing provides insight into later or ongoing immune responses. Clinical Importance Testing for IgG Borrelia miyamotoi is particularly useful in patients with: Relapsing fever symptoms such as recurrent fever, chills, sweats, or fatigue Neurological complaints, including headache, meningitis-like symptoms, or confusion A history of tick exposure in areas where Lyme disease and relapsing fever Borrelia overlap (Europe, Asia, North America) Patient Takeaway A positive IgG B. miyamotoi result means your immune system has previously recognized this relapsing fever Borrelia. This does not always indicate an active infection, since IgG antibodies can persist after past exposure. Your healthcare provider will interpret the result in combination with your symptoms, exposure history, and other Borrelia test results to determine next steps. If your result is reported as equivocal (borderline), antibody levels are near the cutoff and the finding is uncertain. In this case, repeat or confirmatory testing may be recommended.
The IgG Babesia test measures antibodies against Babesia species, a group of parasites transmitted by ticks that can cause babesiosis, a malaria-like illness. Babesia microti is the most common species in North America, while Babesia divergens and others are more frequently found in Europe and Asia. What IgG Babesia Means IgG antibodies typically develop several weeks after infection and may remain detectable for months or years, even after treatment. A positive IgG result usually indicates past exposure or immune memory, not necessarily an active infection. IgM antibodies are more reflective of recent or acute babesiosis, while IgG testing provides a view of longer-term immune response. Clinical Importance Testing for IgG Babesia can be helpful in patients who have: Unexplained fevers, sweats, or chills that resemble malaria-like illness Fatigue, anemia, or low platelets, which can result from parasite activity in red blood cells A history of tick exposure, particularly in areas where Lyme disease and babesiosis often occur together (co-infections are common) Persistent or recurrent symptoms after suspected tick-borne infection Patient Takeaway A positive IgG Babesia result means your immune system has previously recognized the parasite, suggesting prior exposure or infection. Since IgG can remain long after illness, this test does not always mean the infection is still active. Your healthcare provider will interpret the result alongside your symptoms, clinical history, and other tests (such as IgM, PCR, or blood smear) to confirm whether babesiosis is present. If the result is equivocal (borderline), antibody levels are close to the cutoff and not clearly positive or negative. In this case, repeat or confirmatory testing is often recommended.